2026/AT/04255/V1

“Hemofiliya xəstəliyi üzrə Tədbirlər Proqramı çərçivəsində dərman vasitələri”nin satın alınması

Buyer:

Who has won this buyer's procurements

From 184 published results of its procurements.

The documentation is paywalled, but the lot items are public. The analysis is built on these.

#	Lot items	Quantity	Unit
1	Emicizumab 150 mq/ml 0.4 ml N1 (Hemlibra) Emicizumab 150 mq/ml 0.4 ml N1 (Hemlibra)	21	qutu

WORTH BIDDING

2 of this buyer's procurements in this category collapsed because too few suppliers bid. Competition here is weak.

Chancecomputed from history

21 procurements, 4 different winners

Wins most often: "ZEYTUN PHARMACEUTİCALS" MƏHDUD MƏSULİYYƏTLİ CƏMİYYƏTİ (13, 61.9%)

Based on: this buyer, this category

Pricecomputed from history

Winners went 0.02% to 85.44% below the estimate, median 5.63%.

For this tender that is AZN 61,227 down to AZN 58,767.

Nobody has ever won below AZN 9,067.

Cost of one attemptfrom the source

AZN 150

Documents AZN 25 + participation AZN 125

The bid bond and your own time come on top of this.

From 184 published results of its procurements.